Global Information
회사소개 | 문의 | 비교리스트

Lenti-D : 신약 인사이트와 시장 예측(2030년)

Lenti-D- Emerging Drug Insight and Market Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 09월 상품 코드 959699
페이지 정보 영문 50 Pages
가격
US $ 3,250 ₩ 3,819,000 PDF (Single User License)
US $ 6,500 ₩ 7,638,000 PDF (Site License)
US $ 9,750 ₩ 11,458,000 PDF (Global License)


Lenti-D : 신약 인사이트와 시장 예측(2030년) Lenti-D- Emerging Drug Insight and Market Forecast - 2030
발행일 : 2020년 09월 페이지 정보 : 영문 50 Pages

Lenti-D; elivaldogene autotemcel(이전 명칭 elivaldogene tavalentivec)는 X-연관 부신백질이영양증 유전자 치료제입니다. 현재 bluebird bio는 제III상 임상시험을 실시하고 있으며, 2020년 말까지 EU 지역내에서의 판매 승인 신청(MAA)을, 2021년 중반에는 미국에서 생물제제 인가 신청(BLA)을 제출할 예정입니다.

미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본 주요 7개국의 Lenti-D 시장을 조사했으며, 2030년까지 전망을 제시하고, 의약품 개요, 시장 평가, SWOT 분석, 경쟁사 각사 개요, 기타 새로운 치료제 등의 정보를 제공합니다.

조사 범위:

  • 제품 설명, 작용기서, 투여량과 투여 방법, 연구개발 활동을 포함한 종합적인 제품 개요
  • 규제기관 승인 절차 마일스톤 등 개발 활동 상세
  • 미국 , 유럽, 일본의 의약품 연구개발 상세
  • Lenti-D에 관한 유효기간을 포함한 특허 정보
  • 2030년까지 Lenti-D 매출 예측
  • 개발 후기 단계(제III상)에 있는 새로운 치료제의 종합적인 정보
  • 애널리스트의 견해와 SWOT 분석

보고서 하이라이트:

  • 뇌부신백질이영양증(CALD) 치료제 시장 시나리오는 세계 각국에서 진행되고 있는 연구개발과 의료비 증가로 크게 변화하고, 시장 규모 확대에 의해 참여하는 제약회사가 증가할 전망입니다.
  • 기업과 연구자는 Lenti-D 우위성을 높일 기회를 모색하고 있습니다. 현재 개발중인 치료법에서는 병상을 치료/개선하기 위한 새로운 어프로치가 초점이 되고 있습니다.
  • Lenti-D로 경쟁하는 새로운 경쟁 제품이 등장하고 있으며, 조만간 시장에 큰 영향을 미칠 것으로 생각됩니다.

본 보고서에서 대응하고 있는 주요 의문점:

  • Lenti-D를 개발하고 있는 것은 어느 기업인가?
  • Lenti-D 개발에 이용되고 있는 기술은 무엇인가?
  • Lenti-D 제품 종류, 투여 경로, 작용기서는 어떠한 것인가?
  • 임상시험 상황과 완료일은 언제인가?
  • Lenti-D 개발과 관련된 주요 협력, 합병, 인수, 라이선싱 등의 움직임은 어떻게 되고 있는가?
  • Lenti-D에 부여된 주요 지정은 무엇인가?
  • Lenti-D 예측 시장 시나리오는 어떠한 것인가?
  • Lenti-D의 지금까지 움직임과 향후 전망은 어떻게 되는가?
  • 미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본에서의 Lenti-D 매출 예측은 어떻게 되는가?
  • 이용 가능한 기타 신제품은 무엇인가? 또한 이러한 제품은 어떠한 형태로 경쟁하는가?
  • 현재 개발 후기 단계 새로운 치료제는 무엇인가?

목차

제1장 의약품 개요

  • 제품 상세
  • 작용기서
  • 투약과 관리
  • 연구개발 활동
    • 임상 개발
    • 안전성과 유효성
  • 기타 개발 활동

제2장 시장 평가

  • 주요 7개국 시장 분석
  • 미국 시장
  • 독일 시장
  • 프랑스 시장
  • 이탈리아 시장
  • 스페인 시장
  • 영국 시장
  • 일본 시장

제3장 SWOT 분석

제4장 애널리스트의 견해

제5장 시장에서의 경쟁

제6장 기타 새로운 치료제

제7장 부록

제8장 보고서 구입 옵션

KSM 20.09.16

List of Tables

  • Table 1 LENTI-D, Description
  • Table 2 LENTI-D, Clinical Trial Description
  • Table 3 LENTI-D, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of LENTI-D
  • Figure 2 Patent Details, LENTI-D
  • Figure 3 LENTI-D, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 LENTI-D, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 LENTI-D, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 LENTI-D, Japan Market Size from 2020 to 2030 (in Millions USD)

"Lenti-D- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Cerebral Adrenoleukodystrophy (CALD) in 7 Major Markets. A detailed picture of the LENTI-D in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

Elivaldogene autotemcel (formerly elivaldogene tavalentivec) is a gene therapy for X-linked adrenoleucodystrophy. In July 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted an accelerated assessment to eli-cel gene therapy for cerebral adrenoleukodystrophy (CALD). bluebird bio is currently on track to submit the Marketing Authorization Application (MAA) in the EU for eli-cel for CALD by year-end 2020, and the Biologics License Application (BLA) in the U.S. in mid-2021. bluebird bio is currently enrolling patients for a Phase 3 study (ALD-104) designed to assess the efficacy and safety of eli-cel after myeloablative conditioning using busulfan and fludarabine in patients with CALD.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Lenti-D.
  • The report contains forecasted sales for Lenti-D till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Cerebral Adrenoleukodystrophy (CALD).
  • The report also features the SWOT analysis with analyst insights and key findings of Lenti-D.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Lenti-D Analytical Perspective by DelveInsight

  • In-depth Lenti-D Market Assessment

This report provides a detailed market assessment of Lenti-D in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • Lenti-D Clinical Assessment

The report provides the clinical trials information of Lenti-D covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Cerebral Adrenoleukodystrophy (CALD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Lenti-D dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Cerebral Adrenoleukodystrophy (CALD) are giving market competition to Lenti-D and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of Lenti-D.
  • Our in-depth analysis of the forecasted sales data of Lenti-D from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Lenti-D.

Key Questions:

  • Which company is developing Lenti-D along with the phase of the clinical study?
  • What is the technology utilized in the development of Lenti-D?
  • What is the product type, route of administration and mechanism of action of Lenti-D?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Lenti-D development?
  • What are the key designations that have been granted to Lenti-D?
  • What is the forecasted market scenario of Lenti-D?
  • What is the history of Lenti-D and what is its future?
  • What is the forecasted sales of Lenti-D in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to Lenti-D?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

Back to Top
전화 문의
F A Q